Cardiopulmonary Devices Market valued at US$ 2.8 billion in 2021 and is set to witness a healthy CAGR of 5% by 2026

1
Cardiopulmonary Devices Market to Obtain Steady
Growth by 2026
2
Cardiopulmonary diseases include a variety of
conditions that affect the heart and lungs.
Heart-lung machines (HLM), percutaneous
ventricular assist devices (PVAD), extracorporeal
membrane oxygenation (ECMO) Autotransfusion
(ATS) are included in the Cardiopulmonary
devices. These devices are used during cardiac
surgeries, pulmonary surgeries, congenital
defects, cardiopulmonary bypass procedures,
cardiogenic shock/respiratory failure, joint
replacement surgeries, aneurysm surgeries,
transplants, and other indications. The Global
Cardiopulmonary Devices Market valued at US 2.8
billion in 2021 is set to witness a growth rate
of 5 in the next 5 years. Some of the major
factors influencing the global cardiopulmonary
devices market include growing geriatric
population, rising incidence of cardiopulmonary
diseases, surge in demand for cardiopulmonary
devices due to Covid-19, rise in the number of
ECMO centers, growing awareness of
cardiopulmonary devices, and rising cases of
complex cardiac surgeries. However, the dearth of
perfusionists in key markets such as the U.S. is
likely to hamper the growth of the
market. Favourable Impact of Covid-19 on the
Cardiopulmonary Devices Market The majority of
Covid-19 virus-infected individuals during
20202021 showcased moderate symptoms and
recovered quickly. However, some patients
developed severe respiratory failure and required
intensive care unit (ICU) admission and
mechanical ventilation. ECMO has emerged as a
promising treatment option for these severely ill
Covid-19 patients, helping to treat and save
their lives. The ECMO machine supports both the
heart and lungs and stabilizes patients to allow
their bodies more time to fight the virus.
3
Increasing awareness about ECMO, HLM other
cardiopulmonary devices and the implementation of
new ECMO centers during the COVID-19 pandemic
further boosted the global cardiopulmonary
devices market. Favorable Regulatory Policies in
Key Markets Boosted the Cardiopulmonary Devices
Market To fight the Covid-19 pandemic and to
offer cardiopulmonary and advanced circulatory
support products and therapies that may benefit
Covid-19 virus-infected patients, in April 2020
the FDA permitted manufacturers of
cardiopulmonary bypass devices to modify the
product indications for use to include ECMO
therapy for greater than six hours, without prior
submission of a premarket notification to FDA.
Sales of cardiopulmonary and advanced circulatory
support products grew as a result of the
favorable regulatory policy shift. ECMO has
emerged as a game-changer for Covid-19 patients.
It has proven to be a life saver. More than 200
patients at our hospital who have been on ECMO
longer than 24 hours have recovered. - Director,
Mechanical Circulatory Support ECMO, Leading
Hospital, United States Explore Premium Report
on Cardiopulmonary Devices Market
_at_ https//meditechinsights.com/cardiopulmonary-dev
ices-market/ Technological Advancements Drive
the Cardiopulmonary Devices Market The market for
cardiopulmonary devices is technology-driven and
characterized by constant product
enhancements/innovations.
4

• For instance,
• In April, 2022, LivaNova initiates the targeted
  commercial launch of the Essenz Patient Monitor
  for cardiopulmonary bypass procedures. The
  transformative monitoring system uses a
  patient-tailored approach to improve clinical
  efficiency and quality of patient care during
  cardiopulmonary bypass (CPB) procedures
• In January 2021, Eurosets announced the full
  commercial release (out of USA) of its novel
  ECMOlife system for ExtraCorporeal Life Support
  (ECLS). ECMOlife expands Eurosets portfolio to
  provide temporary support to patients in
  different therapeutic areas, including
  ExtraCorporeal Membrane Oxygenation (ECMO) and
  Mechanical Circulatory Support (MCS)
• Organic and Inorganic Growth Strategies Adopted
  by Players to Establish Their Foothold
• The cardiopulmonary devices market is
  characterised by the presence of both established
  and new players. Companies operating in the
  market adopt both organic and inorganic growth
  strategies such as acquisitions, and new product
  launches to garner market share.
• For instance,
• In February 2022, Getinge acquired 100 of the
  equity interest in Talis Clinical LLC, a US-based
  leading innovator of High Acuity cloud-based
  software solutions. Talis Clinicals offer is
  designed to support and document care throughout
  the general and cardiac perioperative care
  process, but also through labor and delivery
  episodes and critical care support including ECMO
  Therapy

5

• In October 2021, MicroPort acquired 100 of the
  equity held by existing shareholders of Hemovent
  GmbH. Hemovent specializes in the development of
  ground-breaking Extracorporeal Life Support
  (ECLS) systems
• The cardiopulmonary devices market is anticipated
  to expand in the coming years as a result of an
  increase in cardiopulmonary cases, technological
  advancements in cardiopulmonary devices, rising
  number of orthopaedic transplant procedures,
  and rising aging populations.
• Competitive Landscape Analysis of Cardiopulmonary
  Devices Market
• The global cardiopulmonary devices market is
  marked by the presence of players such
  as LivaNova, Getinge, Terumo, Medtronic, Abbott,
  Abiomed, Haemonetics, Fresenius, among others.
• For More Detailed Insights, Contact Us
  _at_ https//meditechinsights.com/contact-us/
• About Medi-Tech Insights
• Medi-Tech Insights is a healthcare-focused
  business research insights firm. Our clients
  include Fortune 500 companies, blue-chip
  investors hyper-growth start-ups. We have
  completed 100 projects in Digital Health,
  Healthcare IT, Medical Technology, Medical
  Devices Pharma Services.
• Contact
• Ruta Halde
• Associate, Medi-Tech Insights
• 32 498 86 80 79
• info_at_meditechinsights.com